Association between increased dispensing of opioid agonist therapy take-home doses and opioid overdose and treatment interruption and discontinuation

Healthcare disruptions and physical distancing measures put in place in response to the COVID-19 pandemic prompted concerns around access to opioid agonist therapy (OAT). On March 22, 2020, Ontario released new guidance recommending that clinicians extend the number of take-home OAT doses to their patients.

This study examines whether pandemic-specific guidance to increase access to take-home doses of OAT was associated with changes in treatment retention and opioid-related harms among OAT recipients in Ontario, Canada.

Access the full article and associated resources:

Please note that this report is NOT COMPLETE and is still in progress. Click below if you would like to continue.